Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 12/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.53 |
| ▸ | KDM5A | P29375 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17037034 | 1.00 | CA1 (0.54) | CA1CA2CA12CA9EPHX2 | |
| SCHEMBL9893075 | 0.88 | EPHX2 (0.67) | EPHX2EPHX1 | |
| SCHEMBL23573410 | 0.86 | EPHX2 (0.51) | CA1CA2CA12CA9EPHX2 | |
| SCHEMBL23573495 | 0.86 | EPHX2 (0.51) | CA1CA2CA12CA9EPHX2 | |
| SCHEMBL5746611 | 0.86 | EPHX2 (0.51) | CA1CA2CA12CA9EPHX2 | |
| SCHEMBL3457791 | 0.86 | CA1 (0.53) | CA1CA2CA12CA9EPHX2 | |
| SCHEMBL3458723 | 0.86 | CA1 (0.53) | CA1CA2CA12CA9EPHX2 | |
| SCHEMBL23142562 | 0.86 | CA1 (0.53) | CA1CA2CA12CA9EPHX2 | |
| SCHEMBL13207164 | 0.84 | EPHX2 (0.50) | CA1CA2CA12CA9EPHX2 | |
| SCHEMBL24371501 | 0.83 | KDM5A (0.49) | CA1CA2CA12CA9EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. | 2022-12-08 | — | — | US | disclosed |
| EP-3760630-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2021-01-06 | — | — | EP | disclosed |
| WO-2020210828-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-3269716-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-09-16 | — | — | EP | disclosed |
| EP-3269716-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2018-01-17 | — | — | EP | disclosed |
| EP-2970255-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-08-02 | — | — | EP | disclosed |
| WO-2017040450-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| US-8481750-B2 | Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-09 | — | — | US | disclosed |
| US-20120178734-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-12 | — | — | US | disclosed |
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7488752-B2 | nor-seco himbacine derivatives; thrombosis, anticoagulants, anticancer agents; antiinflammatory agents; anticholesterol agents; cardiovascular disorders; antiarrhythmia agents; antiischemic agents; strokes; antiarthritic agents | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| EP-0218249-B1 | PROCESS FOR THE PRODUCTION OF 3-AMINOPYRROLIDINES | Tokyo Kasei Kogyo Co., Ltd (JP) | 1992-08-12 | — | — | EP | disclosed |
| US-4785119-A | AMINATION, CYCLIZATION | TOKYO KASEI KOGYO CO., LTD. (JP) | 1988-11-15 | — | — | US | disclosed |
| EP-0218249-A2 | Process for the production of 3-aminopyrrolidines | Tokyo Kasei Kogyo Co., Ltd (JP) | 1987-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | CA1 4280/4885CA2 2118/4885CA12 3217/4885 |
| US-20120178734-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | ARG1, COL14A1, HPGDS | CA1 583/4885CA2 293/4885CA12 1543/4885 |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | EIF2AK4, GCN1, GNAI2 | CA1 4599/4885CA2 2277/4885CA12 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.